Drugs / PF-08103402
last change Jun 2026 re-read 2 minutes ago

PF-08103402

Developed for
asthma
Investigated by
Pfizer

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07660731 Jun 2026 → Jun 2027 expected asthma Pfizer Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PF-08103402 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660731
Route Oral “The study medicine will be taken as a suspension or tablet by mouth 1 time a day” NCT07660731